NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM